Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. HBEGF OverCol2 mice have normal body weight and body length.
  • Fig. S2. HBEGF OverCol2 mice overexpress HBEGF in cartilage.
  • Fig. S3. HBEGF OverCol2 mice have normal joint structure.
  • Fig. S4. Overexpressing HBEGF in articular cartilage does not affect long bone structure.
  • Fig. S5. Mesenchymal progenitors in synovium are not affected by HBEGF overexpression in cartilage.
  • Fig. S6. Overexpressing HBEGF in cartilage does not affect cartilage matrix composition and cartilage degradation.
  • Fig. S7. Overexpressing HBEGF in cartilage does not affect vital internal organs.
  • Fig. S8. HBEGF OverAgcER mice have increased HBEGF expression and EGFR activity in knee articular cartilage.
  • Fig. S9. Synthesis and characterization of PLL-PCL.
  • Fig. S10. TGFα-NPs result in similar morphology changes in chondrocytes as free TGFα.
  • Fig. S11. TGFα-NPs are functional on human articular cartilage.
  • Fig. S12. TGFα-NPs doped with PLL-PCL enhance bovine cartilage uptake.
  • Fig. S13. TGFα-NPs doped with PLL-PCL improve their penetration and retention in bovine cartilage tissue.
  • Fig. S14. Biodistribution of TGFα-NPs within the knee joints and some major organs.
  • Fig. S15. TGFα-NP treatment attenuates OA progression after DMM surgery in mice.
  • Fig. S16. TGFα-NP treatment starting at 1 month after DMM attenuates further OA progression.
  • Fig. S17. The mechanism underlying the protective action of EGFR overactivation on articular cartilage after DMM surgery.
  • Fig. S18. Intra-articular injections of TGFα-NPs for 2 months do not affect vital internal organs and gross joint morphology.
  • Table S1. Mouse real-time PCR primer sequences.
  • References (5559)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: